A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of first-line nivolumab plus ipilimumab treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) in Italy
Non-small Cell Lung Cancer (NSCLC)
DRUG: Nivolumab + ipilimumab
Overall survival (OS), Up to 5 years
Progression-free survival (PFS), Up to 5 years|Overall response rate (ORR), Up to 5 years|Best overall response (BOR), Up to 5 years|Best overall response rate (BORR), Up to 5 years|Tumor response to treatment as classified by the treating physician and Response Evaluation Criteria in Solid Tumors (RECIST) criteria, Up to 5 years|Duration of response (DOR), Up to 5 years|Time to response (TTR), Up to 5 years|European Quality of Life-5 Dimensions (EQ-5D) Score, Baseline and up to 5 years|Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) results, Baseline and up to 5 years|Treatment regimen, Up to 5 years|Stage IV or recurrent, not previously treated, squamous and non-squamous NSCLC as confirmed by histology and/or cytology test results, Baseline|Number of participants discontinuing treatment, Up to 5 years|Management of Adverse Events (AEs), Up to 5 years|Participant socio-demographic characteristics, Baseline and up to 5 years|Participant clinical characteristics, Baseline and up to 5 years
The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of first-line nivolumab plus ipilimumab treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) in Italy